MHRA Updates Gene Therapy Rules, Launches AI Manufacturing Support; FDA Expands Quality Testing, Global Data Sharing

Regulators in the United Kingdom and United States unveiled four major policy shifts this week, modernizing gene therapy definitions, supporting AI-driven manufacturing, expanding drug quality surveillance, and opening FDA review packages to foreign agencies.

The Medicines and Healthcare products Regulatory Agency (MHRA) published the outcome of its consultation on updating the legal definition of gene therapy medicinal products (GTMPs) under the Human Medicines Regulations 2012, a framework last revised in 2007, European Pharmaceutical Review reported.

The existing rules have struggled to encompass genome-editing tools such as CRISPR-Cas9 and synthetic nucleic acid therapies, creating classification ambiguity for advanced therapy medicinal products (ATMPs). MHRA intends to lay the necessary legislation to implement the changes, aligning the regulatory perimeter with current scientific reality.

UK Law to Recognize Genome-Editing as Gene Therapy

  • UK law will soon recognize genome-editing treatments as gene therapies, clearing a regulatory path for CRISPR and similar technologies to reach NHS patients.
  • A new MHRA pilot program will give developers of personalized medicines and AI manufacturing earlier feedback, aiming to cut costly late-stage redesigns.
  • The FDA will test more drugs from pharmacy shelves using modern screening, while sharing its full review dossiers with foreign regulators to speed global approvals.

On Monday, the MHRA launched AdvanceGxP, a service backed by Office for Life Sciences funding that offers early regulatory and quality guidance for developers of personalized medicine manufacturing, robotics, automation, and artificial intelligence. A specialist team will build and test the service, though initial capacity will be limited while the approach is evaluated. The goal is to address compliance questions before they become expensive obstacles in late-stage development.

Simultaneously, the US Food and Drug Administration (FDA) activated its Enhanced Approach for Sampling and Testing (EAST) initiative. The program combines modern analytical screening with traditional laboratory methods to broaden the range of therapeutic classes, manufacturers, and geographic regions covered by quality surveillance. FDA inspectors will collect samples from retail pharmacies and wholesale distributors, assessing identity, purity, and potency to trigger faster regulatory action and inform future inspection priorities.

On Tuesday, the FDA launched the Global Reliance Disclosure Programme (GRDP), allowing sponsors to obtain minimally redacted approval packages — including detailed scientific and regulatory assessments — for sharing with non-US authorities. The program opens first for certain tentative approvals under the President’s Emergency Plan for AIDS Relief (PEPFAR), excluding tentatively approved abbreviated new drug applications.

Sponsors must opt in within ten calendar days of approval and confirm the documentation supports a foreign marketing application. The agency plans to expand eligibility to all novel drug applications and biologics licence applications in January 2027, with a pathway for already approved products to follow early that year.

Initiative Agency Scope Key Timeline
GTMP Definition Update MHRA (UK) Gene therapy, genome editing, synthetic nucleic acids Legislation to follow consultation outcome
AdvanceGxP MHRA (UK) Personalized manufacturing, robotics, AI Pilot phase; limited initial capacity
EAST FDA (US) Retail/wholesale drug sampling, modern screening Active as of 18 November 2026
GRDP FDA (US) Disclosure of approval packages to foreign regulators PEPFAR tentative approvals now; all NDAs/BLAs January 2027

The MHRA’s definition overhaul responds directly to the explosion of in vivo and ex vivo genome-editing platforms that did not exist when the ATMP regulation was drafted.

Developers should note that initial capacity constraints mean early engagement slots will be competitive; the agency has signaled it will prioritize platforms with near-term clinical translation potential.

The FDA’s EAST initiative represents a methodological shift from reactive, for-cause testing to proactive, risk-based surveillance.

The ten-day opt-in window is tight; sponsors must build disclosure readiness into their regulatory strategy at the point of FDA submission.

Patients Should Not Change Prescribed Treatments

These regulatory changes do not alter clinical indications for any specific therapy. Patients should not change or stop prescribed treatments based on policy announcements. Individuals enrolled in gene therapy clinical trials should discuss any questions about reclassification or manufacturing changes with their principal investigator or treating physician. Consumers who experience unexpected side effects from any medication should report them via the MHRA Yellow Card scheme or FDA MedWatch immediately.

The Medicines and Healthcare products Regulatory Agency was formed in 2003 by merging the Medicines Control Agency and the Medical Devices Agency to create a single UK regulator. Following the UK’s withdrawal from the European Union, it assumed independent licensing responsibilities previously handled through EU frameworks.

In December 2020, it became the first regulator worldwide to grant temporary authorisation for the Pfizer–BioNTech COVID-19 vaccine. In 2023, it again led globally by approving Casgevy, a CRISPR-based gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassaemia, directly relevant to the new GTMP definitions.

The MHRA has not yet published the draft statutory instrument that will amend the 2012 Regulations, and the FDA has not detailed the analytical validation package for EAST’s modern screening tier. Both gaps will determine how quickly developers can operationalize the new pathways.

References

  • MHRA. Government backs modernisation of gene therapy definitions. Published 19 November 2026.
  • MHRA. MHRA AdvanceGxP service: building compliance into innovation earlier. Published 18 November 2026.
  • US Food and Drug Administration. FDA introduces new approach for drug quality sampling and testing. Published 18 November 2026.
  • US Food and Drug Administration. FDA launches Global Reliance Disclosure Program to expand patient access to medicines worldwide. Published 17 November 2026.
Photo of author

Health Desk

Health Desk at Archyde.

Blade Director Bassam Tariq Tells The New Arab He Left Marvel Over Incomplete Script